SEONGNAM, South Korea, Sept. 22, 2020 The data from the low dose cohort confirms the safety and efficacy of BBT-401, Bridge Biotherapeutics' novel drug candidate for ulcerative colitis patients Bridge Biotherapeutics discloses plans to initiate the mid to high dose cohort trials of the...
from PR Newswire: https://ift.tt/33PtEyZ
No comments:
Post a Comment